HC Wainwright Issues Pessimistic Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at HC Wainwright decreased their FY2026 EPS estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn $2.05 per share for the year, down from their prior estimate of $2.15. HC Wainwright has a “Buy” rating and a $165.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.83 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.98 EPS, Q2 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.94 EPS, Q4 2027 earnings at $1.05 EPS, FY2027 earnings at $3.39 EPS, FY2028 earnings at $6.76 EPS, FY2029 earnings at $9.58 EPS and FY2030 earnings at $12.92 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.84 by $0.17. The company had revenue of $340.47 million during the quarter, compared to analysts’ expectations of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The business’s revenue was up 64.0% on a year-over-year basis. During the same quarter last year, the business earned $0.16 EPS.

CORT has been the topic of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $173.00 price objective (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday. Canaccord Genuity Group boosted their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Truist Financial started coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price target for the company. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research note on Monday, July 27th. Finally, Weiss Ratings raised Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $139.50.

Corcept Therapeutics Stock Down 9.6%

Shares of Corcept Therapeutics stock opened at $71.63 on Friday. The firm has a market cap of $7.84 billion, a price-to-earnings ratio of 56.40 and a beta of 0.54. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $126.38. The company’s 50-day simple moving average is $108.46 and its 200-day simple moving average is $75.47.

Insider Activity

In other Corcept Therapeutics news, insider William Guyer sold 16,300 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $113.43, for a total value of $1,848,909.00. Following the sale, the insider owned 3,985 shares of the company’s stock, valued at approximately $452,018.55. This represents a 80.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean Maduck sold 30,955 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $125.58, for a total value of $3,887,328.90. Following the completion of the transaction, the insider owned 9,755 shares of the company’s stock, valued at approximately $1,225,032.90. This represents a 76.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 382,536 shares of company stock valued at $43,406,554 in the last 90 days. Insiders own 20.70% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Corcept Therapeutics during the 2nd quarter valued at about $27,000. State of Wyoming raised its position in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 186 shares during the last quarter. Provenance Wealth Advisors LLC purchased a new stake in shares of Corcept Therapeutics in the third quarter valued at about $38,000. Gould Capital LLC lifted its holdings in shares of Corcept Therapeutics by 66.7% in the first quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Fulcrum Asset Management LLP lifted its holdings in shares of Corcept Therapeutics by 520.7% in the third quarter. Fulcrum Asset Management LLP now owns 571 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 479 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported Q3 earnings of $1.01 per share, above the $0.84 consensus, and revenue of $340.5 million, up 64% year over year and slightly ahead of expectations. Higher Korlym sales and Lifyorli uptake contributed to growth. Article: CORT’s Q3 earnings beat
• Neutral Sentiment: HC Wainwright continues to rate the stock Buy with a $165 target, although it lowered several forecasts. Its longer-term estimates still project earnings growth, including $6.76 per share in 2028 and $12.92 in 2030.
• Negative Sentiment: HC Wainwright cut estimates for Q4 2026 EPS to $0.98 from $1.31 and FY2026 EPS to $2.05 from $2.15. It also reduced its Q2–Q4 2027 quarterly forecasts and lowered FY2027 EPS to $3.39 from $3.95, adding to concerns about the company’s near-term earnings outlook.
• Negative Sentiment: Two insiders sold shares: Roberto Vieira sold 8,333 shares for about $674,000, while Sean Maduck sold more than 25,000 shares across two transactions for roughly $2.05 million. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in company fundamentals. Article: Corcept insider selling
• Negative Sentiment: Shares crossed below their 200-day moving average, a technical signal that may add to selling pressure. Article: CORT crosses below its 200-day moving average

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.